Roundtable Discussion – Distinguish the Regulatory Expectations Regarding Post-Emergency Situations and the Impact on Quality Considering Different Therapeutic Indications
Time: 3:30 pm
day: Conference Day One
Details:
- In recent years, mRNA vaccines have helped control the SARS-CoV-2 pandemic, and mRNA-based therapies have shown remarkable promise in treating a wide range of diseases. This session offers a deep dive into the evolving regulatory landscape surrounding mRNA medicines and its consequential impact on quality control practices.
- We will look at the pre- versus post-COVID pandemic regulatory environment, and then focus on changes in expectations for mRNA quality control and compliance with respect to the therapeutic indication. We will discuss strategies one can adopt to meet these evolving requirements and how to apply these to future prophylactic and therapeutic mRNA vaccines in development.
